Mesoblast Ltd Ord

(MEOBF)

By |

Profile

Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.

Contact Information

Website: www.mesoblast.com
Email: michael.schuster@mesoblast.com
Main Phone: +61 396396036
Address: Level 38, 55 Collins Street
State: VIC
City / Town: Melbourne
Country: AUS
Postal Code: 3000

Issuer Information

Exchange: OTO
CEO: Silviu Itescu
Employees: 83
NAICS: 541711

Equities News

Profile

Mesoblast is a small cap biotech company with listings on both the ASX and the Nasdaq. The company has acquired the rights to develop and commercialize certain regenerative medicine technologies aimed at innovative ways of treating inflammatory diseases. Of their product pipeline, three product candidates are currently in phase three trials, with the first drug in the FDA approval application process and a possible U.S. launch date in early fiscal 2021. The company has sold the rights to develop and commercialize some of its technologies in Japan, Europe and China from which it earns milestone and ongoing licence revenues once the products are marketed. Mesoblast is currently in the R&D phase and is loss-making.

Contact Information

Website: www.mesoblast.com
Email: michael.schuster@mesoblast.com
Main Phone: +61 396396036
Address: Level 38, 55 Collins Street
State: VIC
City / Town: Melbourne
Country: AUS
Postal Code: 3000

Issuer Information

Exchange: OTO
CEO: Silviu Itescu
Employees: 83
NAICS: 541711

Equities News

$ 2.05 $ 0. (0.00%)
Last Price 2.05 Change $ 0. Change % 0.00 Tick N/A
Bid 2.05 Bid Size 100.00 Ask 3.90 Ask Size 900.00
Open N/A High N/A Low N/A Prev Close 2.05
Last Trade Volume 0 52 Wk Hi 3.91 52 Wk Low 0.90
Market Cap 1.2 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 583,949,612.00 EPS (TTM) -0.15 PE Ratio N/A Exchange OTCPK